HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RLAY
Relay Therapeutics, Inc.
There isn't enough reported data to score RLAY yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RLAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RLAY's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RLAY PE Valuation
RLAY has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RLAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RLAY's revenue to decline, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RLAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.50 | +$0.22 |
| Q2 2026 | -$1.56 | +$0.36 |
| Q1 2026 | -$1.56 | +$0.64 |
| Q4 2025 | -$1.61 | +$0.75 |
| Q3 2025 | -$1.72 | +$0.90 |
| Q2 2025 | -$1.92 | +$0.61 |
| Q1 2025 | -$2.20 | +$0.45 |
| Q4 2024 | -$2.36 | +$0.45 |
RLAY has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RLAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RLAY on profitability, with a higher operating margin.
RLAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $350K | -48% |
| Q1 2026 | $3M | -61% |
| Q1 2025 | $7.7M | -23% |
| Q1 2024 | $10M | +4328% |
| Q3 2023 | $25.2M | +7226% |
| Q2 2023 | $119K | -67% |
| Q1 2023 | $226K | -46% |
| Q4 2022 | $253K | -99% |
RLAY's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -25950% | -14599 points |
| Q1 2026 | -2620% | -1515 points |
| Q4 2025 | -866% | N/A |
| Q2 2025 | -11351% | N/A |
| Q1 2025 | -1105% | -202 points |
| Q1 2024 | -903% | +43866 points |
| Q3 2023 | -292% | +24677 points |
| Q2 2023 | -89118% | -67800 points |
RLAY's operating margin was −25950% last quarter, down 24845 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
RLAY has the stronger cash trend. Its trailing FCF is down 7.9% versus its history, compared with HIMS at down 84%.
RLAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$63.9M | -$1.8M |
| Q4 2025 | -$44.9M | +$13M |
| Q3 2025 | -$62.1M | +$13.2M |
| Q2 2025 | -$55.3M | +$10.6M |
| Q1 2025 | -$73.6M | -$21.5M |
| Q4 2024 | -$57.9M | +$31.4M |
| Q3 2024 | -$75.3M | +$677K |
| Q2 2024 | -$65.8M | +$4.3M |
RLAY has burned cash in almost every quarter: −$226M over the past year, against −$273M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RLAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RLAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +16.3M shares |
| 1 year | +27% | +46.8M shares |
| 3 years | +79% | +96.9M shares |
| 5 years | +136% | +126M shares |
RLAY has 219M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RLAY Net Leverage
RLAY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RLAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 43.1 | Neutral |
RLAY's weekly RSI is 55 (neutral) and its Stochastic is 43 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RLAY PE vs Healthcare Sector
RLAY has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RLAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 0.6% above |
| 20 week MA | $18.7 | 3.4% below |
| 50 week MA | $14.2 | 27% above |
| 100 week MA | $9.17 | 97% above |
| 200 week MA | $9.50 | 90% above |
RLAY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RLAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $46.9 | +6.6% |
| 2021 | $46.9 | $33.4 | -29% |
| 2022 | $33.4 | $14.6 | -56% |
| 2023 | $14.6 | $11.0 | -25% |
| 2024 | $11.0 | $4.36 | -60% |
| 2025 | $4.36 | $8.56 | +96% |
| 2026 YTD | $8.56 | $18.1 | +111% |
RLAY has the edge over HIMS on returns for 2026, with the stronger performance.